Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $1,208,000.00 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 40,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $30.20, for a total transaction of $1,208,000.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $735,460.60. The trade was a 62.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $33.24 on Friday. The stock has a fifty day moving average price of $32.80 and a two-hundred day moving average price of $33.14. The company has a market cap of $3.89 billion, a price-to-earnings ratio of -18.57 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 52-week low of $17.97 and a 52-week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million for the quarter. As a group, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on NAMS shares. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Truist Financial assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, NewAmsterdam Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $48.60.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Capital World Investors increased its position in NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the last quarter. Duquesne Family Office LLC lifted its position in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after buying an additional 1,091,525 shares during the last quarter. Castle Hook Partners LP bought a new position in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $38,062,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of NewAmsterdam Pharma by 96.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock worth $60,536,000 after acquiring an additional 845,110 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.